ORIGINAL RESEARCH
Accepted on 16 Oct 2025
A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving durvalumab in combination with tremelimumab
doi 10.3389/fimmu.2025.1657398
- 174 views
- Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Research Topics
- Community Series in Reducing Adverse Effects of Cancer Immunotherapy: Volume III
Community Series in Reducing Adverse Effects of Cancer Immunotherapy: Volume III
5,416
Total downloads
32k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
CORRECTION
Published on 08 Oct 2025
Correction: Real-world outcomes of immune checkpoint inhibitors as second-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective analysis
doi 10.3389/fimmu.2025.1708889
- 322 views
ORIGINAL RESEARCH
Accepted on 02 Oct 2025
Signal mining and analysis of influencing factors for adverse events of Nivolumab and Cetuximab in the treatment of head and neck cancer based on the US FAERS database
doi 10.3389/fimmu.2025.1658535
- 151 views
ORIGINAL RESEARCH
Published on 29 Sep 2025
Real-world disproportionality analysis of cardiac failure associated with novel antineoplastic agents in breast cancer: a pharmacovigilance study
doi 10.3389/fimmu.2025.1680909
- 8,712 views
ORIGINAL RESEARCH
Published on 19 Sep 2025
Real-world outcomes of immune checkpoint inhibitors as second-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective analysis
doi 10.3389/fimmu.2025.1658017
- 1,261 views
CASE REPORT
Published on 18 Sep 2025
Case report and literature review: tislelizumab combined with lenvatinib and polymeric micellar paclitaxel for thymic squamous cell carcinoma
doi 10.3389/fimmu.2025.1677723
- 1,212 views
BRIEF RESEARCH REPORT
Published on 01 Sep 2025
Associations between chemoradiotherapy-based immune checkpoint blockade and posttreatment depression and anxiety in head and neck cancer patients: a cross-sectional study
doi 10.3389/fimmu.2025.1649486
- 1,007 views
ORIGINAL RESEARCH
Published on 29 Jul 2025
Risk factors and long-term prognostic impact of immune related pancreatic injury in patients receiving immune checkpoint inhibitors
doi 10.3389/fimmu.2025.1590992
- 1,118 views
PERSPECTIVE
Published on 25 Jul 2025
The regulatory effects of PD-1/PD-L1 inhibitors on bone metabolism: opportunities and challenges in osteoporosis management
doi 10.3389/fimmu.2025.1630751
- 2,009 views
ORIGINAL RESEARCH
Published on 08 Apr 2025
Adverse drug reaction assessment of pembrolizumab in cervical cancer treatment: a real-world pharmacovigilance study using the FAERS database
doi 10.3389/fimmu.2025.1582050
- 3,568 views
ORIGINAL RESEARCH
Published on 18 Mar 2025
Clinical features of nivolumab-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: retrospective analysis based on case reports
doi 10.3389/fimmu.2025.1563100
- 2,051 views
ORIGINAL RESEARCH
Published on 07 Mar 2025
Immune checkpoint inhibitors and cancer-related cognitive decline: a propensity score matched analysis in active chemotherapy patients
doi 10.3389/fimmu.2025.1540442
- 2,665 views
Published in
Frontiers in Immunology
Cancer Immunity and Immunotherapy
Participating Journals
Frontiers in Oncology
- 3.3 impact factor
- 6.9 citescore
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
Select the journal/section where you want your idea to be submitted: